New Employee Elected Directors to the Board of Zealand Pharma A/S

Udgivet den 13-03-2024  |  kl. 21:00  |  

Company announcement - No. 14 / 2024

New Employee Elected Directors to the Board of Zealand Pharma A/S

Copenhagen, Denmark, March 13, 2024 - Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL) (CVR-no. 20 04 50 78). The employees of Zealand Pharma A/S have elected the following employee representatives and alternates for the Company's Board of Directors:

Employee representatives:

Frederik Beck (re-elected)Anneline Nansen (re-elected)Ludovic Otterbein (newly elected) Adam Nygaard (newly elected)

As alternates for the employee-elected board members, the following were elected:

Tanja ErichsenKatja HansenLars PedersenCecilie Kold

The new employee-elected board members will join the Board of Directors following the annual general meeting of Zealand Pharma A/S on 20 March 2024. At the same time the current board members Jens Peter Stenvang, who did not run for election, and Louise Gjelstrup, who did not run for election, will step down from their positions on the Board.

About employee-elected board members

According to the Danish Companies Act, the employees of Zealand Pharma A/S are entitled to be represented by half of the total shareholder-elected Board members. Employee-elected board members serve for a statutory four-year term and have the same rights, duties and responsibilities as shareholder-elected board members.

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) (Zealand) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of blue-chip pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand's business and activities, please visit www.zealandpharma.com.

Contact:

Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: ank@zealandpharma.com


\Hugin

Udgivet af: NPinvestordk

Seneste nyheder

09:29 Biden og Trump langer ud efter containerrederier efter strejke
09:22 Vestas får snittet kursmålet hos Danske Bank: Skuffende ordreindgang rammer indtjeningen i 2025 og 2026
09:07 Aktier/åbning: DSV får hovedrolle på skæbnedag i lysegrøn start
08:51 Zealand Pharma får dugfrisk hold-anbefaling af Deutsche Bank
08:45 Obligationer/åbning: Renterne kravler forsigtigt op fra start
08:22 Råvarer: Olieprisen stiger efter eskalering af konflikten i Mellemøsten
08:19 Aktier/tendens: Afdæmpet start i sigte på skæbnedag for DSV - Vestas får sænkede kursmål
08:09 Teslas salgstal kan flytte aktiekursen vurderer Nordnet
08:06 Københavns Lufthavn har haft sin travleste september nogensinde
07:53 Vestas får skåret lille bid af kursmål hos Deutsche Bank
07:15 Obligationer/tendens: Nervøsiteten fordufter langsomt - udsigt til stigende renter
07:00 Jefferies skærer over 27 pct. af kursmålet hos Vestas
06:33 Asien: Jubel på børsen i Hongkong - aktier sendes op med over 6 pct. på kinesisk lukkedag
06:32 Valuta: Dollar holder fast i styrkelse oven på eskalering i Mellemøsten
06:32 USA/T-bond: Investorer søgte ly i obligationer og sendte renterne ned
06:32 USA/lukning: Optrappet konflikt i Mellemøsten sendte aktierne ned - Apple faldt tungt
06:30 Kalender med link - onsdag den 2. oktober
17:52 Europa/lukning: Tysk kemikaliekoncern sendt op efter købstilbud
17:37 Samsung nærmer sig fyringsrunde i Sydøstasien og Australien
17:02 Tirsdagens aktier: Bekymring for situationen i Mellemøsten satte ekstra fart på nedturen